Organon Pharma Indonesia Tbk. vs Sarana Menara Nusantara Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Sarana Menara Nusantara Tbk. trades at Rp454 (market cap 27.07T, 48.95M 24h volume). The key difference: Sarana Menara Nusantara Tbk. is far larger — about 259.3× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | TOWR | |
|---|---|---|
Market Cap | 104.4B | 27.07T |
Volume | — | 48.95M |
Lot | — | 489.54K |
Turnover | — | 22.1B |
Average Price | — | 451.36 |
Value | — | 22.1B |
Indicative Equilibrium Price | — | 454 |
Indicative Equilibrium Volume | — | 12.16K |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT Sarana Menara Nusantara Tbk (the company) was established based on Deed of Establishment (Article of Association) No.31 dated June 2, 2008 drawn up in the presence of Dr. Irawan Soerodjo, S.H., MSi., Notary in Jakarta.The Company's articles of association has been amended several times, most recently by notarial deed No. 71 of Irawan Soerodjo, S.H., dated Nov 18, 2009, concerning among others, the change in par value, and public offering
Read more on TOWR →